Growth inhibition of ras‐dependent tumors in nude mice by a potent ras‐dislodging antagonist

Y. Egozi,B. Weisz,M. Gana‐Weisz,G. Ben-Baruch,Y. Kloog

DOI: https://doi.org/10.1002/(SICI)1097-0215(19990315)80:6<911::AID-IJC18>3.0.CO;2-4

1999-03-15

International Journal of Cancer

Abstract:A lipophilic farnesyl moiety attached to the carboxyl terminal cysteine of ras proteins structurally supports their membrane anchorage, required for ras‐dependent growth‐factor signaling and for transforming activity of ras oncoproteins. It has been shown that inhibition of ras farnesylation can block tumor growth in nude mice but that some ras‐dependent tumors escape such blockage as a result of prenylation of ras. S‐trans‐transfarnesylthiosalicylic acid (FTS) is a potent ras‐dislodging antagonist that does not affect ras prenylation but rather acts on the mature, membrane‐bound ras and facilitates its degradation. Here we demonstrate that FTS induces reappearance of stress fibers in H‐ras‐transformed rat‐1 cells (EJ cells) in vitro, inhibits their anchorage‐independent growth in vitro, and blocks EJ‐tumor growth in nude mice. The anchorage‐independent growth of cells expressing ErbB2 (B104), but not that of v‐raf‐transformed cells, is also inhibited by FTS, suggesting specificity towards activated ras. FTS treatment (5 mg/kg i.p. daily) caused inhibition (75–80%) of tumor growth in nude mice implanted with EJ, but not in mice implanted with v‐raf‐transformed cells, with no evidence of systemic toxicity. Moreover, FTS treatment increased the survival rate of EJ‐tumor‐bearing mice from 48 to 68 days. Here we demonstrate anti‐tumor potency in a synthetic, non‐toxic, ras‐dislodging antagonist acting independently of farnesyltransferases. Int. J. Cancer 80:911–918, 1999. © 1999 Wiley‐Liss, Inc.